Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
21 hedge funds and large institutions have $37.8M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 20 → 21 (+1)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
45% less capital invested
Capital invested by funds: $68.2M → $37.8M (-$30.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.53M |
| 2 |
Citigroup
New York
|
+$1.36M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$887K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$50.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.77M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.18M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$107K |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$43.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$13K |
LBPH Hedge Fund Activity: Q4 2021 in Review
21 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q4 2021, worth a combined $37.8M — down 45% from $68.2M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LBPH positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.53M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.77M.
- 21 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q4 2021, up from 20 in Q3 2021.
- Funds reported $37.8M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 45% quarter-over-quarter.
- 3 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 2 closed out, a net change of +1 holder.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Millennium Management, an estimated $1.53M added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was T. Rowe Price Associates, an estimated $1.77M sold.
Based on aggregated 13F filings for Q4 2021.